<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167661</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0661 (2003-0493)</org_study_id>
    <nct_id>NCT00167661</nct_id>
  </id_info>
  <brief_title>Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation</brief_title>
  <official_title>Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Campath-1H induction and the associated
      lymphocyte depletion will permit long-term rejection-free renal allograft survival in the
      absence of ongoing corticosteroid administration.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment suspended pending protocol revision to change study to observational
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of graft rejection and graft loss</measure>
    <time_frame>at 1, 3, 6, 12, and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>at 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection and malignancy</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth post-transplant</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypertension and hyperlipidemia</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>at 6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of diabetes mellitus</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Campath 1-H</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campath-1H</intervention_name>
    <description>two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, aged 18 months - 18 years inclusive.

          2. Subjects must be a single-organ recipient (kidney only).

          3. Subjects who are receiving their first living donor or deceased donor transplant.

        Exclusion Criteria:

          -  1. Subjects who are recipients of HLA-identical living-donor renal transplants. 2.
             Subjects with a PRA value &gt; 10% within 30 days prior to the transplant. 3. Subjects
             who have received a multi-organ transplant. 4. Subjects who are who are positive for
             hepatitis C, hepatitis B surface antigen or HIV.

             5. Subjects who have received an investigational drug within 6 weeks of study entry.

             6. Subjects who have a previous history of, or who currently have, malignancies and/or
             lymphoma.

             7. Subjects who have received corticosteroids within three months of transplantation.

             8. Subjects who are 3rd transplant recipients. 9. Female subjects who are pregnant or
             lactating. Fertile female subjects who are sexually active must agree to use an
             acceptable method of birth control during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon M Bartosh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon M Bartosh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>October 9, 2015</last_update_submitted>
  <last_update_submitted_qc>October 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>living or deceased donor renal transplant recipient</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

